Show simple item record

dc.contributor.authorGlynn, D
dc.contributor.authorBliss, J
dc.contributor.authorBrunt, AM
dc.contributor.authorColes, CE
dc.contributor.authorWheatley, D
dc.contributor.authorHaviland, JS
dc.contributor.authorKirby, AM
dc.contributor.authorLongo, F
dc.contributor.authorFaria, R
dc.contributor.authorYarnold, JR
dc.contributor.authorGriffin, S
dc.date.accessioned2022-11-23T09:12:41Z
dc.date.available2022-11-23T09:12:41Z
dc.date.issued2022-11-17
dc.identifier.citationBreast Cancer Research and Treatment, 2022,en_US
dc.identifier.issn0167-6806
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5568
dc.identifier.eissn1573-7217
dc.identifier.eissn1573-7217
dc.identifier.doi10.1007/s10549-022-06802-1
dc.identifier.doi10.1007/s10549-022-06802-1
dc.description.abstract<jats:title>Abstract</jats:title><jats:sec> <jats:title>Purpose</jats:title> <jats:p>We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in either 15 (WB15F, PB15F) or 5 fractions (WB5F, PB5F). In a subgroup ineligible for PB radiotherapy, we compared WB15F to WB5F.</jats:p> </jats:sec><jats:sec> <jats:title>Methods</jats:title> <jats:p>We developed a Markov cohort model to simulate lifetime healthcare costs and quality-adjusted life years (QALYs) for each modality. This was informed by the clinical analysis of two non-inferiority trials (FAST Forward and IMPORT LOW) and supplemented with external literature. The primary analysis assumed that radiotherapy modality influences health only through its impact on locoregional recurrence and radiotherapy-related adverse events.</jats:p> </jats:sec><jats:sec> <jats:title>Results</jats:title> <jats:p>In the primary analysis, PB5F had the least cost and greatest expected QALYs. WB5F had the least cost and the greatest expected QALYs in those only eligible for WB radiotherapy. Applying a cost-effectiveness threshold of £15,000/QALY, there was a 62% chance that PB5F was the cost-effective alternative in the PB eligible group, and there was a 100% chance that WB5F was cost-effective in the subgroup ineligible for PB radiotherapy.</jats:p> </jats:sec><jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Hypofractionation to 5 fractions and partial breast radiotherapy modalities offer potentially important benefits to the UK health system.</jats:p> </jats:sec>
dc.languageen
dc.language.isoengen_US
dc.publisherSpringer Science and Business Media LLCen_US
dc.relation.ispartofBreast Cancer Research and Treatment
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.titleCost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysisen_US
dc.typeJournal Article
dcterms.dateAccepted2022-10-18
dc.date.updated2022-11-22T15:38:03Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1007/s10549-022-06802-1en_US
rioxxterms.licenseref.startdate2022-11-17
rioxxterms.typeJournal Article/Reviewen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-statusPublished online
pubs.publisher-urlhttp://dx.doi.org/10.1007/s10549-022-06802-1
icr.researchteamClin Trials & Stats Uniten_US
dc.contributor.icrauthorBliss, Judith
icr.provenanceDeposited by Mrs Jessica Perry (impersonating Prof Judith Bliss) on 2022-11-22. Deposit type is initial. No. of files: 1. Files: HE paper published version - breast cancer research and treatment Nov 2022.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/